What Incyte's Quarter ended Sep 30, 2026 10-Q says: 2 signals
Incyte filed its latest 10-Q with the SEC on Oct 29, 2026. It discusses acquisition completed and product launch.
Public (INCY)Pharmaceutical Manufacturing5,001 to 10,000 employeesincyte.comLinkedIn
Get Incyte's live signals in Claude or ChatGPT, or by API
What changed at Incyte this week? Use Autobound signals for incyte.com.- Filed
- Oct 29, 2026
- Period
- Quarter ended Sep 30, 2026
- Filings
- 3
- Signals
- 22
Source: Autobound Signal API · 75 signals tracked for Incyte · updated
10-Q · latest 10
What Incyte's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 30, 2026
Filed · 2 signals
Completed acquisition of Vega Therapeutics Inc. in July 2026
Incyte completed the acquisition of Vega Therapeutics Inc., adding latarcibart to its hematology pipeline.
FDA approved JAKAFI XR extended release tablets in May 2026
In May 2026, the FDA approved JAKAFI XR extended release tablets across multiple indications including myelofibrosis and polycythemia vera.
- SEC EDGAR
10-Q
Filed · 9 signals
Incyte appoints Suketu Upadhyay as new Executive Vice President and Chief Financial Officer.
Incyte forms AI collaboration with Genesis Molecular AI to accelerate drug discovery.
Incyte is strategically investing in artificial intelligence for R&D, highlighted by a new collaboration with Genesis Molecular AI in May 2026.
Artificial IntelligenceGenesis Molecular AI
Incyte partners with Genesis Molecular AI to leverage its generative AI platform for drug discovery.
In May 2026, Incyte entered a collaboration with Genesis Molecular AI, indicating active investment in AI to accelerate R&D.
AIgenerative AIpredictive AIGenesis Molecular AI
Incyte reports it frequently defends against and responds to data security attacks and incidents.
The company admits its IT systems are under frequent attack, including from ransomware, creating a persistent pain point around data security.
cybersecurityransomware
Incyte is making "substantial capital expenditures" to enhance IT systems for planned growth.
The company is actively upgrading its IT systems to support growth and manufacturing operations, which involves significant capital spending.
Incyte faces significant financial risk up to 4% of global revenue from data privacy laws like GDPR.
The company highlights the severe financial penalties for noncompliance with data privacy laws like GDPR and HIPAA.
$20M
Potential fine for noncompliance under GDPR in the EU
4%
Potential fine of annual global revenue under GDPR
cybersecurity
Incyte increasing investment in Artificial Intelligence to maintain competitiveness
artificial intelligenceGenesis Molecular AI
Incyte faces patent challenges from generic drug competitors for key products JAKAFI and OPZELURA.
The company is under direct competitive pressure from generic drug manufacturers challenging patents for its major revenue-generating products.
Earlier 10-Q filings
- 10-QFiled · 11 signalsSEC EDGAR
Showing 10 of 22 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Incyte earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Raised full-year revenue guidance after strong quarterThe company increased its full-year 2025 net product revenue guidance to over $4.2 billion, reflecting strong sales momentum and financial health. This indicates ample budget for strategic investments and new vendor solutions. | |
| Preparing for three major new product launches in 2026Three significant products are launching next year, which will require substantial investment in commercial infrastructure, including sales force preparations, payer engagements, and medical education initiatives. | |
| CEO launching company-wide cost review to improve margins and reallocate capitalLeadership is conducting a review of the entire business focused on prioritization and data-driven trade-offs to manage costs. This creates opportunities for solutions that improve ROI, offer cost savings, or provide better data for financial decision-making. | |
| Creating 'ring-fenced' budgets for non-negotiable growth programsLeadership is explicitly protecting budgets for strategic growth drivers, including new product launches and key R&D projects, designating them as 'nonnegotiable, fully funded programs' for the 2026 budget and beyond. | |
| CEO implementing strategic review to reallocate capital to high-value projectsA company-wide review is underway to shift spending from low-value areas to high-return opportunities. This creates an opening for vendors whose solutions can demonstrate clear ROI and alignment with core growth drivers. | |
| Announced strong 20% Y/Y revenue growthTotal revenues grew 20% to $1.37 billion, driven by strong performance across key products. This rapid growth provides significant operating leverage and capital to fund new initiatives. |
Signal API · MCP
Track Incyte with the Signal API
One POST /v1/companies/enrich call with incyte.com returns Incyte 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"incyte.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about Incyte 10-Q
When did Incyte file its latest 10-Q?
What did Incyte disclose in its latest 10-Q?
What did Incyte say on its recent earnings calls?
Where can I read Incyte's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .